Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Painless Laser Therapy for Overactive Bladder (PLTOAB)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2012 by Zipper Urogynecology Associates.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Ralph Zipper, MD, Zipper Urogynecology Associates Identifier:
First received: March 26, 2012
Last updated: March 29, 2012
Last verified: March 2012
The primary objective of this study is to determine the effectiveness of transvaginally-delivered low level laser therapy (LLLT) versus Sham in the treatment of overactive bladder symptoms in women. The secondary objective is to determine the effect of transvaginally-delivered LLLT vs. sham on the quality of life.

Condition Intervention
Overactive Bladder
Device: LCT-1000TM (Manufacturer: LiteCure)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Sham-controlled, Multicenter Clinical Trial to Assess the Effectiveness of Therapeutic Class IV Laser LCT-1000TM Treatment for Overactive Bladder Syndrome.

Resource links provided by NLM:

Further study details as provided by Zipper Urogynecology Associates:

Primary Outcome Measures:
  • The primary efficacy endpoint will be the improvement of OAB symptoms and general quality of life due to the effect of LLLT treatment on OAB through week 7. [ Time Frame: Visits 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 (over approximately 7 weeks) ]
    Patients will undergo 3 LLLT procedures per week for 3 weeks, for a total of 9 LLLT procedures.

  • The primary safety endpoint will evaluate the SLG and ALG treatment groups for differences in reported side effects and adeverse events throughout the trial, including LLLT treatment and follow-up. [ Time Frame: Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13 (over approximately 8 weeks) ]
    Patients will undergo 3 LLLT procedures per week for 3 weeks, for a total of 9 LLLT procedures.

Estimated Enrollment: 200
Study Start Date: February 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Active Laser Group (ALG) Device: LCT-1000TM (Manufacturer: LiteCure)
low level laser therapy (LLLT)
Sham Comparator: Sham Laser Group (SLG) Device: LCT-1000TM (Manufacturer: LiteCure)
low level laser therapy (LLLT) sham treatment

Detailed Description:

This study is a double-blind, randomized, sham-controlled, multicenter, clinical trial that will include enrollment of up to 200 subjects at up to 3 investigational sites.

The study population will be randomized at a 1:1 ratio into two groups: Sham Laser Group (SLG) and Active Laser Group (ALG). The Sham Laser Group will receive a sham LLLT procedure (no laser energy) and the Active Laser Group will receive an active LLLT procedure (laser energy).

Both groups will undergo 3 LLLT procedures per week for 3 weeks, for a total of 9 LLLT procedures. Whether the procedure will be a sham procedure (placebo) or an active LLLT application will be determined by randomization which will assign subjects to be treated with an LCT-1000TM labeled either Laser A or Laser B. The only difference between Laser A and Laser B is that one does not emit laser energy; therefore, both subjects and site research personnel will be blinded as to whether laser energy is actually applied to the subject.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject is female and at least 18 years of age at screening.
  • A score of > 4 on the OAB-q short form for urgency.
  • The subject has an average urinary frequency of > 10 voids per day.
  • Self-reported bladder symptoms for > 3 months.
  • Self-reported failed conservative care.
  • The subject has discontinued all antimuscarinics for at least 2 weeks prior to screening.
  • The subject is ambulatory and able to use the toilet independently and without difficulty.
  • Negative pregnancy test in subjects of childbearing potential.
  • Subject attests in writing that she has not had unprotected intercourse within 3 weeks prior to study enrollment and agrees to have no intercourse until treatments conclude.
  • Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study.
  • The subject (and caregiver, if applicable) is willing to participate in this study for at least 7 weeks.
  • The subject is otherwise in general good health with no other major medical conditions.

Exclusion Criteria:

  • The subject has vaginal bleeding.
  • The subject has urinary or gastric retention or a neurogenic bladder.
  • The subject is not capable of completing study questionnaires or undergoing portions of the study.
  • The subject has been sexually assaulted.
  • The subject has an alcohol or drug addiction.
  • The subject has used isotretinoin (Accutane) within 6 months prior to study enrollment.
  • The subject has cancer.
  • The subject has used Botox® in the bladder or pelvic floor muscles within 12 months prior to study enrollment.
  • The subject currently has a urinary tract infection or vaginal infection.
  • The subject is using Interstim® or Bion®.
  • Current use of TENS in pelvic region, back or legs.
  • The subject is pregnant or lactating, or is of childbearing potential unless she is surgically sterile or she and/or her partner are using a medically acceptable method of birth control.
  • Any use of light-activated drugs (photodynamic therapy) or heat sensitive medications within 30 days of first treatment.
  • The subject has used an investigational drug/device therapy or participated in any clinical investigation involving or impacting gynecologic, urinary, or renal function within 4 weeks prior to study enrollment.
  • The subject is otherwise determined, based on the opinion of the Investigator, to be an unsuitable candidate for enrollment in this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01569061

Contact: Ralph Zipper, MD 321-674-2114
Contact: James Raders, MD 321-674-2114

United States, Florida
Zipper Urogynecology Associates Recruiting
Melbourne, Florida, United States, 32901
Contact: Ralph Zipper, MD    321-674-2114   
Contact: James Raders, MD    321-674-2114   
Principal Investigator: Ralph Zipper, MD         
Sponsors and Collaborators
Zipper Urogynecology Associates
Principal Investigator: Ralph Zipper, MD Zipper Urogynecology Associates
  More Information

Additional Information:
Responsible Party: Ralph Zipper, MD, Principal Investigator, Zipper Urogynecology Associates Identifier: NCT01569061     History of Changes
Other Study ID Numbers: 11-179
Study First Received: March 26, 2012
Last Updated: March 29, 2012

Keywords provided by Zipper Urogynecology Associates:
overactive bladder
laser therapy
urinary incontinence
urinary urgency

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms processed this record on April 25, 2017